Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of thiazolidone derivative in preparing anti-rhabdomyosarcoma medicines

A technology for rhabdomyosarcoma and thiazolidinone is applied in the application field of thiazolidinone derivatives in the preparation of anti-rhabdomyosarcoma drugs, and can solve problems such as adverse reactions of chemotherapy drugs, neurotoxicity and the like

Inactive Publication Date: 2014-02-05
SHANDONG UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, chemotherapy drugs have serious adverse reactions, such as gastrointestinal reactions, bone marrow suppression, neurotoxicity, etc. (quoted from Song Enfeng et al., Toxic and side effects of chemical anticancer drugs and treatment with traditional Chinese medicine, "Journal of Guiyang College of Traditional Chinese Medicine", 2008 Year 01)
However, 4-thiazolidinone is used to develop broad-spectrum anticancer drugs, evaluate drug efficacy and pharmacology research, and has been retrieved by authoritative organizations (SCI / SSCI / A&HCI / ESI, BIOSIS / Inspec / JCR database and CNKI database). Not yet reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of thiazolidone derivative in preparing anti-rhabdomyosarcoma medicines
  • Application of thiazolidone derivative in preparing anti-rhabdomyosarcoma medicines
  • Application of thiazolidone derivative in preparing anti-rhabdomyosarcoma medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Preparation of 2-(4-hydroxyphenylimino)-5-(3-methoxybenzylidene)-4-thiazolidinone

[0035] by HCl:H 2 The ratio of O (1:4) is made into hydrochloric acid solution. Weigh 11.4g (150mmol) of ammonium thiocyanate and dissolve it in 50mL of hydrochloric acid solution, add 10.9mL (100mmol) of 4-hydroxyaniline, and heat to 85°C with stirring, the mixture becomes clear. After 12 hours of reaction, TLC monitors the reaction. After the reaction, the mixture was cooled to room temperature, and a viscous oily liquid appeared, which was extracted with ethyl acetate, and the extract was washed with 10% hydrochloric acid solution, saturated sodium chloride solution, and water successively, and the solvent was evaporated off the extract under reduced pressure to obtain Viscous oily liquid, 4-hydroxyphenylthiourea.

[0036] Add 4.24g of 4-hydroxyphenylthiourea and 9.15g of anhydrous sodium acetate into 35mL of ethanol, add 5.13g of ethyl chloroacetate under stirring condit...

Embodiment 2

[0041] Example 2: Determination of the half inhibitory concentration of 2-(4-hydroxyphenylimino)-5-(3-methoxybenzylidene)-4-thiazolidinone on cancer cell growth by SRB method

[0042] 5% CO at 37°C 2 Three cancer cells, Hela, HCT-116, and RD, were cultured in DMEM / 10% fetal bovine serum medium under the condition of . Three kinds of cancer cells in the logarithmic phase were collected and seeded in 96-well plates respectively, and incubated for 24 hours. Add different concentrations (20, 10, 5, 1, 0.1, 0.01 μM) of 2-(4-hydroxyphenylimino)-5-(3-methoxybenzylidene)-4-thiazolidinone ( Compound I) After incubation for 48 hours, 50 μL of trichloroacetic acid solution (30%) was added and fixed at 4°C for one hour. Shake off the solution, rinse with high-purity water five times, add 100 μL sulforhodamine B to stain for 30 minutes after drying, rinse with 1% acetic acid solution five times after drying. After drying, add 100 μL of Tris solution to fully dissolve, and measure the ab...

Embodiment 3

[0043] Example 3: Determination of the effect of 2-(4-hydroxyphenylimino)-5-(3-methoxybenzylidene)-4-thiazolidinone on cancer cell cycle by PI staining flow cytometry

[0044] Hela, HCT-116, and RD cancer cells in the logarithmic growth phase were inoculated into 6 cm culture dishes at an amount of 200,000 cells per 3 mL of medium volume. After culturing for 24 hours, each cancer cell group was treated with DMSO and 5.0 μM 2-(4-hydroxyphenylimino)-5-(3-methoxybenzylidene)-4-thiazolidinone (Compound I) deal with. After incubation for 24 h, the cells were digested on ice, and the cell suspension was collected, washed twice with PBS after centrifugation. Add 10 mL of 70% ice ethanol to suspend at -20°C overnight. Centrifuge the cell suspension, wash twice with PBS, add 500 μL PI / 5 μL RNAaseA to the cell mass and stain at 4°C for half an hour in the dark. The DMSO group was used as a negative control, and the cell cycle was detected by flow cytometry with standard procedures. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a thiazolidone derivative in preparing broad-spectrum anticancer medicines. The thiazolidone derivative is 2-(4-hydroxyphenylimido)-5-(3-metoxyphenylmethylene)-4-thiazolidone. The broad-spectrum anticancer medicines are preferably medicines with favorable anticancer activity for cervical carcinoma, colon cancer and rhabdomyosarcoma. The test proves that the thiazolidone compound can effectively inhibit proliferation of cervical carcinoma Hela cells, colon cancer HCT-116 cells and rhabdomyosarcoma RD cells and induce apoptosis; and the inspection on the action target spot detects that the obviously inhibits the formation of microtubules when acting on microtubulins and is hopeful to be developed into broad-spectrum anticancer medicines.

Description

[0001] This application is a divisional application of the application with publication number CN103054859A, the application date of the original application: 2013-01-16, the application number: 201310016506.7, the title of the invention: the application of a thiazolidinone derivative in the preparation of broad-spectrum anticancer drugs. technical field [0002] The present invention relates to the application of a novel thiazolidinone derivative in the preparation of broad-spectrum anticancer drugs, in particular to a 2-(4-hydroxyphenylimino)-5-(3-methoxybenzylidene Application of )-4-thiazolidinone in the preparation of broad-spectrum anti-cancer (anti-cervical cancer, colon cancer, rhabdomyosarcoma) drugs. Background technique [0003] Cancer, also known by other terms as malignant tumor or neoplasm, is a group of diseases that can affect any part of the body. A defining feature of cancer is the rapid production of abnormal cells that extend beyond the boundaries of thei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/426A61P35/00
Inventor 闫兵穆岩田聪吴金梅张斌
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com